Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis.

Amber C StreifelLuke C StrnadMonica K SikkaCara D VarleyJina MakadiaEllie SukermanAlyse H DouglassHeather MayerKathleen YoungJames S Lewis

Published in: Open forum infectious diseases (2024)

Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.

Keyphrases

bone mineral density
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
emergency department
electronic health record
big data
postmenopausal women
free survival
artificial intelligence
deep learning